Geneva-based team working on malaria drug

Ms. Cotran said the MMV had been working with around 280 scientists and partnered with organisations in about 50 countries including Tanzania, Uganda, and India.

November 03, 2012 01:17 pm | Updated 01:17 pm IST - MANGALORE:

Medicines for Malaria Venture (MMV), a network of Public-Private Partnership based in Geneva, has been working with several Indian Institutes to speed up the process of developing drugs to fight malaria, MMV Executive Vice-president (Operations) Diana Cotran has said.

Speaking at the awards ceremony of the MMV Drawing Competition here on Friday, Ms. Cotran said it had taken 15 years to develop the drugs. MMV had been working with several research institutes in the world, including those in India to speed up the process. It was working with the National Institute of Malaria Research and with the Centre for Scientific and Industrial Research. Four years ago, the MMV had carried out clinical trials with the assistance of Kasturba Medical College, she said.

Ms. Cotran said the MMV had been working in malaria-affected areas in countries such as Tanzania, Uganda, and India. Since 1999, the MMV had worked with around 280 scientists and partnered with organisations in about 50 countries.

Appreciating the paintings by children, Ms. Cotran said they revealed a lot of things and showed a commitment to fight Malaria. Dean of Kasturba Medical College M.V. Prabhu and S. Nandagopal, the convenor of Centre for Integrated Learning, spoke.

Earlier, a group of students presented a song on malaria prevention. This was followed by a skit and Yakshagana on the same theme. Prizes were given to 10 of 100 best paintings drawn by the children. As many as 5,642 children from 24 schools participated in the drawing competition, which had been held recently for those aged between 10 and 15.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.